Soluble Human Leukocyte Antigen-G in the Bronchoalveolar Lavage of Lung Cancer Patients;Antígeno leucocitario humano-G soluble en el lavado broncoalveolar de pacientes con cáncer pulmonar

Archivos de Bronconeumologia

Volumn 52, Issue 8, 2016, Pages 420-424

  Montilla, Dayana ^a   Pérez, Mario ^a   Borges, Lérida ^b   Bianchi, Guillermo ^b   Cova, José Angel ^b  

^a Hospital Universitario de Los Andes   (Venezuela)

^b UNIVERSIDAD DE LOS ANDES   (Venezuela)

Author keywords

Bronchoalveolar Lavage; Human Leukocyte Antigen G; Karnofsky index; Lung cancer

Indexed keywords

EOSIN; HEMATOXYLIN; LEUKOCYTE ANTIGEN; LEUKOCYTE ANTIGEN G; UNCLASSIFIED DRUG; HLA G ANTIGEN; TUMOR MARKER;

AGE; ARTICLE; BRONCHOSCOPY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENDER; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LUNG BIOPSY; LUNG CANCER; LUNG LAVAGE; METASTASIS; METASTATIC LUNG CANCER; SMOKING; STAINING; ADENOCARCINOMA; AGED; BRONCHOALVEOLAR LAVAGE FLUID; CHEMISTRY; FEMALE; IMMUNOLOGY; LUNG; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SMALL CELL CARCINOMA; SOLUBILITY; SQUAMOUS CELL CARCINOMA; ADULT; AGE DISTRIBUTION; ANTIGEN DETECTION; CANCER CLASSIFICATION; CANCER TISSUE; DISEASE ASSOCIATION; FIBEROPTIC BRONCHOSCOPY; FUNCTIONAL STATUS; LUNG ADENOCARCINOMA; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; BRONCHOALVEOLAR LAVAGE FLUID; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HLA-G ANTIGENS; HUMANS; KARNOFSKY PERFORMANCE STATUS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SMOKING; SOLUBILITY;

EID: 85027240260     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2016.06.018     Document Type: Article

References (29)

1. 1 Rojas W, Anaya JM, Aristizabal B, Cano L, Gómez L, Lopera D. Antígenos y su presentación a los linfocitos. Inmunología de Rojas. 16 ed. Medellín, Colombia: Corporación para Investigaciones Biológicas, CIB; 2012. pp 113-118.
2. 2 Carosella, E., Favier, B., Rouas-Freiss, N., Moreau Ph, LeMaoult, J., Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood. 111 (2008), 4862–4870.
3. 3 Colonna, M., Navarro, F., Bellon, T., Llano, M., García, P., Samaridis, J., et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 186 (1997), 1809–1818.
4. 4 Rojas W, Anaya JM, Aristizabal B, Cano L, Gómez L, Lopera D. Inmunología de la Reproducción. Inmunología de Rojas. 16 ed. Medellín, Colombia: Corporación para Investigaciones Biológicas, CIB; 2012. pp 203.
5. 5 Kovats, S., Main, E.K., Librach, C., Stubblebine, M., Fisher, S.J., deMars, R., A class I antigen. HLA-G, expressed in human trophoblasts. Science. 248 (1990), 220–223.
6. 6 Bainbridge, D.R., Ellis, S.A., Sargent, I.L., HLA-G suppresses proliferation of CD4(+) T-lymphocyte. J Reprod Immunol. 48 (2000), 17–26.
7. 7 Riteau, B., Rouas-Freiss, N., Menier, C., Paul, P., Dausset, J., Carosella, E.D., HLA-G2-G3 and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol. 166 (2001), 5018–5026.
8. 8 Gros, F., Cabillic, F., Toutirais, O., Maux, A., Sebti, Y., Amiot, L., Soluble HLA-G molecules impair natural killer/dendritic cell crosstalk via inhibition of dendritic cells. Eur J Immunol. 38 (2008), 742–749.
9. 9 Albert, A., Samet, J., Epidemiology of lung cancer. Chest. 123:Suppl. (2003), 21S–49S.
10. 10 Paul, P., Rouas-Freiss, N., Khalil-Daher, I., Moreau, P., Riteau, B., Le Gal, F., et al. HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA. 95 (1998), 4510–4515.
11. 11 Urosevic, M., Kurrer, M., Kamarashev, J., Mueller, B., Weder, W., Burg, G., et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology. Human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol. 159 (2001), 817–824.
12. 12 Ye, S.R., Yang, H., Li, k, Dong, D.D., Lin, X.M., Yie, S.M., Human leukocyte antigen G expression: As a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 20 (2007), 375–383.
13. 13 Yie, S.M., Yang, H., Ye, S.R., Li, K., Dong, D.D., Lin, X.M., Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol. 128 (2007), 1002–1009.
14. 14 Nuckel, H., Rebmann, V., Durig, J., Duhrsen, U., Grosse-Wilde, H., HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 105 (2005), 1694–1698.
15. 15 Cao, M., Yie, S.M., Liu, J., Ye, S.R., Xia, D., Gao, E., Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens. 78 (2011), 120–128.
16. 16 Provatopoulou, X., Kalogera, E., Sagkriotis, A., Zagouri, F., Nonni, A., Zografos, G.C., et al. Soluble human leukocyte antigen-G expression in patients with ductal and lobular breast malignancy. Anticancer Res. 32 (2012), 1021–1026.
17. 17 Yates, J., Chalmer, B., McKegney, F., Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 45 (1980), 2220–2224.
18. 18 Lee, G., Special staining techniques. Luna, L.G., (eds.) Manual of Histologic Staining Methods of the Armed Forces. Institute of Pathology, 3th ed., 1968, MacGraw-Hill Book Company, USA, 274–283.
19. 19 McCullang, P., Nelder, J.A., Generalized Linear Models. 2nd ed., 1999, Chapman, Hall/CRC, New York, USA, 511.
20. 20 Morandi, F., Levreri, I., Bocca, P., Galleni, B., Raffaghello, L., Ferrone, S., et al. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 67 (2007), 6433–6441.
21. 21 Schutt, P., Schutt, B., Switala, M., Bauer, S., Stamatis, G., Opalka, B., et al. Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol. 71 (2010), 489–495.
22. 22 Luque, J., Torres, M., Aumente, M., Marín, J., García-Jurado, G., González, R., et al. Soluble HLA-G in heart transplantation: Their relationship to rejection episodes and immunosuppressive therapy. Hum Immunol. 67 (2006), 257–263.
23. 23 Basturk, B., Karakayali, F., Emiroglu, R., Sozer, O., Haberal, A., Bal, D., et al. Human leukocyte antigen-G, a new parameter in the follow-up of liver transplantation. Transplant Proc. 38 (2006), 571–574.
24. 24 Park, Y., Park, Y., Lim, H., Kim, Y., Hong, D., Kim, H., Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma. Tissue Antigens. 79 (2012), 97–103.
25. 25 Tahan, F., Patiroglu, T., Plasma soluble human leukocyte antigen G levels in asthmatic children. Int Arch Allergy Immunol. 141 (2006), 213–216.
26. 26 Torres, M., López-Casado, M., Luque, J., Peña, J., Rios, A., New advances in coeliac disease: Serum and intestinal expression of HLA-G. Int Immunol. 18 (2006), 713–718.
27. 27 Zhang, J., Wang, Z., Chen, J., Wu, X., Zhou, B., Yie, S., The expression of human leukocyte antigen G (HLA-G) is associated with sacroiliitis stages of ankylosing spondylitis. Immunol Lett. 152 (2013), 121–125.
28. 28 Singer, G., Rebmann, V., Chen YCh, Liu, H.T., Ali, S., Reinsberg, J., et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res. 9 (2003), 4460–4464.
29. 29 Crooks, V., Waller, S., Smith, T., Hahn, T., The use of the Karnofsky performance scale in determining outcome and risk in geriatric outpatients. J Gerontol. 46 (1991), 139–144.